Fate Therapeutics Inc
FATE
Get informed when a big investor buys or sells
+ FollowMarket Cap$208.64M
Close$
$-0.51
128.3% downside
Current Fair Value
128.3% downsideOvervalued by 128.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $208.64 Million |
|---|---|
| Enterprise Value | $251.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.15 |
| Beta | 2.53 |
| Outstanding Shares | 120,397,390 |
Return
| Return on Equity | -82.12% |
|---|---|
| Return on Assets | -48.44% |
| Return on Invested Capital | -58.02% |
Valuation & Multiples
| P/E Ratio | -1.7 |
|---|---|
| PEG | 14.85 |
| Price to Sales | - |
| Price to Book Ratio | 1.79 |
| Enterprise Value to Revenue | 38.81 |
| Enterprise Value to EBIT | -1.91 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 0.49 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$1.34 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$1.34 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4453▼ 28.87% |
|---|---|
| Total Calls | 246,100▲ 207.24% |
| Total Puts | 109,600▲ 86.39% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 59.96%▼ 1.78% |
|---|---|
| Total Invested | $194.83M▲ 119.19% |
| Investors Holding | 1620% |
ESG Score
No data
About Fate Therapeutics Inc
CEO: William Rastetter